TTrialPathMatch Me to Trials
← Back to trials
RecruitingOverweight and Obesity

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

Eligible age

18–75 yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in adult with obesity, with or without Type 2 Diabetes (T2D and non-T2D, respectively). In addition, Part B includes two dose groups that will receive WVE-007 and tirzepatide in adults living with obesity and T2D.

Sponsor: Wave Life Sciences USA, Inc.

You may qualify if…

  • ✓ Male and female participants aged 18 to 60 years
  • ✓ BMI 28 to 35 kg/m2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg/ m2 will be allowed.
  • ✓ Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments
  • ✓ Male and female participants aged 18 to 75 years
  • ✓ BMI 35 to 50 kg/m2 (inclusive)
  • ✓ Thyroid stimulating hormone is within normal range at Screening. May be on supplemental thyroid hormone as managed by their prescribing physician and stable within the last 60 days
  • ✓ Participants with or without Type 2 Diabetes (T2D and non-T2D, respectively)

You may not qualify if…

  • ✕ History or presence of CV disease, including heart failure (New York Heart Association \[NYHA\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments
  • ✕ History or presence of thyroid disorders
  • ✕ Medical history or diagnosis of causes of liver disease
  • ✕ Use of any siRNA agent in the prior 12 months
  • ✕ Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study
  • ✕ History of significant CV disease in the opinion of the Investigator.
  • ✕ Use of prescription medications (ie, anti-obesity or psychiatric medications) within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug, except for allowed antihypertensive medications and lipid lowering medications.
  • ✕ Taking \>3 antihypertensive medications, or antihypertensive medication dose was changed in the 60 days prior to Screening.

Where it's recruiting

Arizona

Phoenix

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT06842186 · last updated 2026-10-26

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obes · TrialPath